Egypt · Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 13.17 billion. The enterprise value is 39.79 billion.
| Market Cap | 13.17B |
| Enterprise Value | 39.79B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | Apr 27, 2026 |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Current Share Class | 1.01B |
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -21.13% |
| Owned by Insiders (%) | 26.01% |
| Owned by Institutions (%) | 24.12% |
| Float | 652.98M |
Valuation Ratios
The trailing PE ratio is 15.14 and the forward PE ratio is 10.74. Ibnsina Pharma's PEG ratio is 0.33.
| PE Ratio | 15.14 |
| Forward PE | 10.74 |
| PS Ratio | 0.16 |
| PB Ratio | 4.20 |
| P/TBV Ratio | 4.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 23.38 |
| PEG Ratio | 0.33 |
Enterprise Valuation
| EV / Earnings | 45.72 |
| EV / Sales | 0.48 |
| EV / EBITDA | 10.54 |
| EV / EBIT | 11.63 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 8.81.
| Current Ratio | 1.03 |
| Quick Ratio | 0.66 |
| Debt / Equity | 8.81 |
| Debt / EBITDA | 7.32 |
| Debt / FCF | -43.39 |
| Interest Coverage | 1.51 |
Financial Efficiency
Return on equity (ROE) is 38.93% and return on invested capital (ROIC) is 10.27%.
| Return on Equity (ROE) | 38.93% |
| Return on Assets (ROA) | 5.84% |
| Return on Invested Capital (ROIC) | 10.27% |
| Return on Capital Employed (ROCE) | 68.25% |
| Weighted Average Cost of Capital (WACC) | 7.55% |
| Revenue Per Employee | 15.10M |
| Profits Per Employee | 158,241 |
| Employee Count | 5,500 |
| Asset Turnover | 2.27 |
| Inventory Turnover | 7.76 |
Taxes
In the past 12 months, Ibnsina Pharma has paid 142.85 million in taxes.
| Income Tax | 142.85M |
| Effective Tax Rate | 11.73% |
Stock Price Statistics
The stock price has increased by +22.26% in the last 52 weeks. The beta is 0.72, so Ibnsina Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +22.26% |
| 50-Day Moving Average | 12.29 |
| 200-Day Moving Average | 11.46 |
| Relative Strength Index (RSI) | 52.72 |
| Average Volume (20 Days) | 15,989,789 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 83.04 billion and earned 870.32 million in profits. Earnings per share was 0.86.
| Revenue | 83.04B |
| Gross Profit | 6.73B |
| Operating Income | 3.42B |
| Pretax Income | 1.22B |
| Net Income | 870.32M |
| EBITDA | 3.62B |
| EBIT | 3.42B |
| Earnings Per Share (EPS) | 0.86 |
Balance Sheet
The company has 1.02 billion in cash and 27.64 billion in debt, with a net cash position of -26.62 billion or -26.41 per share.
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 27.64B |
| Net Cash | -26.62B |
| Net Cash Per Share | -26.41 |
| Equity (Book Value) | 3.14B |
| Book Value Per Share | 3.11 |
| Working Capital | 958.63M |
Cash Flow
In the last 12 months, operating cash flow was 563.55 million and capital expenditures -1.20 billion, giving a free cash flow of -636.85 million.
| Operating Cash Flow | 563.55M |
| Capital Expenditures | -1.20B |
| Depreciation & Amortization | 192.23M |
| Net Borrowing | 483.60M |
| Free Cash Flow | -636.85M |
| FCF Per Share | -0.63 |
Margins
Gross margin is 8.11%, with operating and profit margins of 4.12% and 1.29%.
| Gross Margin | 8.11% |
| Operating Margin | 4.12% |
| Pretax Margin | 1.47% |
| Profit Margin | 1.29% |
| EBITDA Margin | 4.35% |
| EBIT Margin | 4.12% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.16, which amounts to a dividend yield of 1.23%.
| Dividend Per Share | 0.16 |
| Dividend Yield | 1.23% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | 31.93% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.23% |
| Earnings Yield | 6.61% |
| FCF Yield | -4.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Ibnsina Pharma is 17.26, which is 31.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 17.26 |
| Price Target Difference | 31.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 13.82% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |
Scores
Ibnsina Pharma has an Altman Z-Score of 2.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 4 |